ENMD-2076: Phase II data

Researchers at Princess Margaret Cancer Centre reported data from 11 evaluable patients with advanced or metastatic STS in the open-label, single-arm, Canadian Phase II Study 2076-STS-001 showing that once-daily oral ENMD-2076 led to a CBR of 27%, including 2 durable partial responses lasting >6 months and 1 case of stable disease lasting >6 months. Median PFS was 1.9 months and median OS has not yet been reached. Grade 3/4 toxicities included hypertension and diarrhea. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...